Real‐world evaluation of automated insulin delivery therapy in type 1 diabetes: A multicentre study across regional and metropolitan Queensland, Australia
Diabetes, Obesity and Metabolism · 2025-08 · 27 (8) · 4436-4445
DOI: 10.1111/dom.16485 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 28.05.2025. Verfasst von Akash Konantambigi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Mackay Hospital and Health Service, Mackay, Queensland, Australia. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulin, Insulin Infusion Systems, Hypoglycemic Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Automated insulin delivery (AID) systems, which integrate continuous glucose monitoring (CGM) with automated insulin dosing, have emerged as a transformative therapy. However, real‐world data on AID effectiveness, particularly in regional Australia, remain limited.
Methods
We conducted a retrospective audit across three Australian hospital sites—Logan (metropolitan), Mackay and Townsville (regional)—to evaluate the impact of AID therapy in adults with Type 1 Diabetes Mellitus (T1DM). Data on demographics, comorbidities, CGM metrics and clinical outcomes were extracted from medical records and device platforms. The primary outcome was change in HbA1c and CGM time‐in‐range (TIR; 3.9–10 mmol/L) at follow‐up. Follow‐up data were recorded up to 12 months following AID commencement. Secondary outcomes included changes in body weight, glycaemic variability and predictors of HbA1c reduction.
Results
The study consisted of 158 people living with T1DM who were initiated on AID. Following AID initiation, mean TIR improved from 53.4% (SD 21.1%) to 70.0% (SD 14.6%) ( p < 0.0001), and time in hyperglycaemia (>13.9 mmol/L) declined from 18.7% (SD 19.4%) to 8.4% (SD 9.31%) ( p < 0.0001). The mean HbA1c significantly decreased from 8.62% (SD 1.70) at baseline to 7.34% (SD 1.31) at follow‐up across the entire study cohort ( p < 0.0001), with 42.7% achieving
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mackay Hospital and Health Service, Mackay, Queensland, Australia.
- James Cook University, Townsville, Queensland, Australia.
- Logan Hospital Metro South Health, Loganholme, Queensland, Australia.
- Townsville University Hospital, Townsville, Queensland, Australia.
ORCID-Profile: Harshal Deshmukh
Zitieren
APA
Konantambigi, A., Wang, W., Boggild, D., Rana, A., Syphers, L., Presley, C., Cummins, C., Malabu, U., Hawke, K., Shenoy, V., Puri, G., & Deshmukh, H. (2025). Real‐world evaluation of automated insulin delivery therapy in type 1 diabetes: A multicentre study across regional and metropolitan Queensland, Australia. Diabetes, Obesity and Metabolism, 27(8), 4436-4445. https://doi.org/10.1111/dom.16485
Vancouver
Konantambigi A, Wang W, Boggild D, Rana A, Syphers L, Presley C, et al. Real‐world evaluation of automated insulin delivery therapy in type 1 diabetes: A multicentre study across regional and metropolitan Queensland, Australia. Diabetes, Obesity and Metabolism. 2025;27(8):4436-4445. doi:10.1111/dom.16485
BibTeX
@article{Konantambigi2025,
author = {Konantambigi, Akash and Wang, Wenyong and Boggild, Dylan and Rana, Arushi and Syphers, Larisa and Presley, Catherine and Cummins, Candice and Malabu, Usman and Hawke, Kate and Shenoy, Vasant and Puri, Gaurav and Deshmukh, Harshal},
title = {Real‐world evaluation of automated insulin delivery therapy in type 1 diabetes: A multicentre study across regional and metropolitan Queensland, Australia},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
volume = {27},
number = {8},
pages = {4436--4445},
doi = {10.1111/dom.16485}
}
EUVIMED